Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803
Akira Inoue(Tohoku University Hospital), Toshihiro Nukiwa(Tohoku University), Hajime Asahina(Hokkaido University), Katsuyuki Hotta(Okayama University Hospital), Akiko Hisamoto(Okayama University), Shoichi Kuyama(Iwakuni Medical Center), Toshiyuki Kozuki(Shikoku Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Kunihiko Kobayashi(Saitama Medical University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masao Harada(Shikoku Cancer Center), Taku Nakagawa(Saint John's Health Center)
Cited by 46
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k